ICU Medical, Inc. — 2018 Form 10-K Summary
Business context and reporting period
Reports the fiscal year ended December 31, 2018; fourth-quarter figures are also disclosed. ICU Medical develops and sells infusion therapy and critical-care products, including pumps, IV consumables, IV solutions, and monitoring systems. The company continued integrating Pfizer’s Hospira Infusion Systems (HIS) business, acquired in February 2017. The acquisition substantially changed the scale and mix of the business, limiting direct comparability with 2016 and affecting 2017 comparisons.
Financial performance and liquidity
| Metric | 2018 | 2017 |
|---|---|---|
| Revenue | $1.400 billion | $1.293 billion |
| Gross profit / gross margin | $570.0 million / 40.7% | $426.1 million / 33.0% |
| Operating income (loss) | $21.6 million | $(15.1) million |
| Net income | $28.8 million | $68.6 million |
| Diluted earnings per share | $1.33 | $3.29 |
| Cash provided by operations | $160.2 million | $154.4 million |
- Revenue increased 8.3% year over year. Infusion Consumables revenue rose 32.1% to $483.0 million; Infusion Systems rose 22.5% to $355.5 million; IV Solutions declined 2.7% to $508.0 million; and Critical Care rose 7.0% to $53.5 million.
- Gross margin improved, which management attributed mainly to product mix and factory efficiencies; 2017 had been affected by HIS acquired-inventory purchase-accounting charges.
- Net income declined despite higher revenue and improved gross margin, reflecting substantial integration and restructuring costs, the partner-contract settlement, and the HIS earn-out remeasurement. 2017 net income included a $70.9 million HIS bargain-purchase gain.
- Fourth-quarter 2018 revenue was $340.4 million and gross profit was $134.6 million, versus $370.1 million and $137.5 million, respectively, in fourth-quarter 2017. Q4 2018 net loss was $7.4 million, compared with net income of $49.7 million a year earlier; the 2017 quarter included the bargain-purchase gain.
- Cash, cash equivalents, and short- and long-term investment securities totaled $384.1 million at year-end; working capital was $677.7 million. Operating cash flow less property, plant, and equipment purchases was approximately $67.5 million.
- There were no borrowings under the $150 million revolving credit facility at year-end, with the full amount available. ICU had repaid the $75 million Pfizer seller note in 2017 and reported compliance with its credit covenants.
Material changes, outlook, risks, and unusual items
- 2018 operating expenses included $105.4 million of restructuring and strategic transaction/integration expense, including $100.9 million related primarily to HIS integration. A $41.6 million contract-settlement charge was also recorded following a dispute with a product partner; the filing describes $28.9 million as the initial net charge and $12.7 million of additional Q4 charges.
- The fair value of the contingent HIS earn-out liability increased to $47.4 million at year-end, with a $20.4 million 2018 expense. Pfizer could receive up to $225 million in cash depending on combined-company performance over the three years ending December 31, 2019.
- Management estimated 2019 capital expenditures of $95 million to $105 million, mainly for manufacturing capacity, customer-placed infusion products, and IT. It stated that cash and expected operating cash flows should fund operations for the next twelve months. No specific revenue or earnings guidance is provided in the filing text.
- Key risks include continued HIS integration and execution, competition and healthcare pricing pressure, reliance on some sole-source materials and concentrated manufacturing sites, regulatory and product-quality requirements, foreign exchange exposure, and international operations. A 10% currency move was estimated to affect reported Euro and Canadian-dollar net assets by approximately $7.1 million and $4.3 million, respectively; those exposures were not hedged.
- ICU was added as a defendant to an intravenous saline antitrust class action and filed a motion to dismiss; Pfizer and ICU have related indemnification claims. The Department of Justice informed the company its separate antitrust investigation was closed in December 2018. A separate DOJ HIPAA subpoena sought records concerning Sapphire infusion pumps, sets, and accessories; ICU said it was coordinating production with Pfizer.
- The company adopted ASC 606 using the modified retrospective method, recording a $6.3 million increase to opening retained earnings. Reported 2018 revenue was $11.1 million higher than it would have been without adoption, according to the filing’s comparison.
- Auditors issued unqualified opinions on the financial statements and internal controls; management also concluded internal controls were effective.
Investor verification priorities
- Check the durability of the 2018 revenue and gross-margin gains, including normalization of IV-solution supply conditions and the extent of growth attributable to HIS integration or accounting classification changes.
- Assess whether integration costs and the contract-partner dispute are substantially complete, and whether further charges or operational disruption remain possible.
- Monitor adjusted performance against the HIS earn-out terms through 2019, the $47.4 million recorded liability, and any potential cash payment up to $225 million.
- Review the status and potential financial exposure of the saline antitrust litigation and the DOJ subpoena relating to Sapphire products.
- Validate 2019 capital-spending plans, operating cash generation, working-capital needs, and continued covenant compliance.